The Efficacy of Flupentixol-Melitracen in the Adjuvant Therapy of Ulcerative Colitis in the Chinese Population: A Meta-Analysis

Xiaoqian Zhou; Lei Zhao; Ping Yang; Yaxi Chen; Xiong Z Ruan

doi:10.1155/2019/3480732

The Efficacy of Flupentixol-Melitracen in the Adjuvant Therapy of Ulcerative Colitis in the Chinese Population: A Meta-Analysis

Gastroenterol Res Pract. 2019 Feb 28:2019:3480732. doi: 10.1155/2019/3480732. eCollection 2019.

Authors

Xiaoqian Zhou^{1

2}, Lei Zhao², Ping Yang², Yaxi Chen², Xiong Z Ruan^{2

3

4}

Affiliations

¹ Department of Gastroenterology, The First People's Hospital of Guiyang, 550000 Guiyang, China.
² Centre for Lipid Research & Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, Department of Infectious Diseases, The Second Affiliated Hospital, Chongqing Medical University, 400016 Chongqing, China.
³ The Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases (CCID), Zhejiang University, 310058 Hangzhou, China.
⁴ John Moorhead Research Laboratory, Centre for Nephrology, University College London Medical School, Royal Free Campus, University College London, London NW3 2PF, UK.

Abstract

Objectives: Our aim of this study is to compare the efficacy of flupentixol-melitracen in the adjuvant therapy of ulcerative colitis patients in the Chinese population.

Methods: Both the RevMan 5.2 and the Stata 12.0 software are used in this study for analysis, and a fixed-effect model (the Mantel-Haenszel method) or a random-effect model (the DerSimonian and Laird method) is used to merge or aggregate the risk ratio (RR) and its 95% confidence intervals (CI) of included studies.

Results: Eleven trials involving 654 ulcerative colitis patients (treated group: 328; control group: 326) were analyzed in this study. Significant differences (RR = 1.29, 95% CI = 1.20 to 1.40, P < 0.001) between patients were observed between the two groups.

Conclusions: Our results suggested that the efficacy of flupentixol-melitracen in the adjuvant therapy of ulcerative colitis is better than traditional drug treatments.

Publication types

Review